Core Viewpoint - The company reported a significant decline in revenue and profit for the nine months ending September 30, 2025, primarily due to decreased sales in intravenous infusion and ampoule injection products, alongside intensified price pressures from expanded procurement initiatives and increased competition in the industry [1] Financial Performance - The company's unaudited revenue for the nine months was approximately HKD 3.102 billion, representing a year-on-year decrease of 31.6% [1] - The unaudited gross profit for the same period was approximately HKD 1.294 billion, down 46.1% year-on-year, with a gross profit margin of 41.7%, a decline of 11.3 percentage points compared to the previous year [1] - The unaudited profit attributable to shareholders for the nine months was approximately HKD 399 million, reflecting a year-on-year decrease of 56.6% [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不會就因本公告全部或任何部份內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：2005） 截至二零二五年九月三十日止九個月 未經審核經營業績 本公告乃石四藥集團有限公司（「本公司」）根據證券及期貨條例（香港法例第571章）第 XIVA部之內幕消息條文（定義見香港聯合交易所有限公司證券上市規則（「上市規則」）） 及上市規則第13.09(2)條而作出。 本公司董事局（「董事局」）根據本公司及其附屬公司（統稱「本集團」）未經本公司核數師 審核或審閱之管理賬目，欣然公告以下本集團截至二零二五年九月三十日止九個月之未 經審核經營業績。 本集團銷售主要在中國進行並以人民幣計值，截至二零二五年九月三十日止九個月，人民幣 兌港元（「港元」）較去年同期貶值約0.9%。以港元而言，本集團截至二零二五年九月三十 日止九個月之未經審核營業額約31.02億港元，同比減少31.6%（本集團截至二零二五年六月 三十日止六個月（「二零二五年上半年」）之收益: 同比減 ...

Core Viewpoint - The company, 石四药集团, announced its intention to bid for 12 products across 14 specifications in the 11th national centralized drug procurement in China scheduled for October 27, 2025 [1] Product Summary - The products intended for bidding include: - 二羟丙茶硷注射液 (2ml:0.3g) - 富马酸福莫特罗吸入溶液 (2ml:20g) - 马来酸氟伏沙明片 (100mg and 50mg) - 注射用氯诺昔康 (8mg) - 盐酸肾上腺素注射液 (1ml:1mg) - 盐酸溴己新注射液 (2ml:4mg) - 复方电解质注射液 (500ml) - 复方电解质注射液 (II) (500ml and 1000ml) - 尼可地尔片 (5mg) - 硫酸沙丁胺醇注射液 (1ml:0.5mg) - 盐酸贝尼地平片 (8mg) - 碳酸氢钠注射液 (50ml:4.2g) [1]

Core Viewpoint - The company, Stone Four Pharmaceutical Group, announced its intention to bid for 14 specifications of 12 products in the 11th national centralized drug procurement in China scheduled for October 27, 2025 [1] Product Summary - The products intended for bidding include: - Dihydrocodeine injection (2ml:0.3g) [1] - Formoterol fumarate inhalation solution (2ml:20µg) [1] - Fluvoxamine maleate tablets (100mg and 50mg) [1] - Chlorzoxazone injection (8mg) [1] - Adrenaline hydrochloride injection (1ml:1mg) [1] - Bromhexine hydrochloride injection (2ml:4mg) [1] - Compound electrolyte injection (500ml) [1] - Compound electrolyte injection II (500ml and 1000ml) [1] - Nicorandil tablets (5mg) [1] - Salbutamol sulfate injection (1ml:0.5mg) [1] - Benidipine hydrochloride tablets (8mg) [1] - Sodium bicarbonate injection (50ml:4.2g) [1]

Core Viewpoint - The company, Stone Four Pharmaceutical Group, announced its intention to bid for 14 specifications of 12 products in China's 11th national centralized drug procurement scheduled for October 27, 2025 [1] Product Summary - The products intended for bidding include: - Dihydrocodeine Injection (2ml: 0.3g) [1] - Formoterol Fumarate Inhalation Solution (2ml: 20μg) [1] - Fluvoxamine Maleate Tablets (100mg and 50mg) [1] - Chlorzoxazone Injection (8mg) [1] - Adrenaline Hydrochloride Injection (1ml: 1mg) [1] - Bromhexine Hydrochloride Injection (2ml: 4mg) [1] - Compound Electrolyte Injection (500ml) [1] - Compound Electrolyte Injection II (500ml and 1000ml) [1] - Nicorandil Tablets (5mg) [1] - Salbutamol Sulfate Injection (1ml: 0.5mg) [1] - Benidipine Hydrochloride Tablets (8mg) [1] - Sodium Bicarbonate Injection (50ml: 4.2g) [1]

本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 自願公告 全國藥品集中採購擬中選結果 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 於二零二五年十月二十七日的中國第十一批全國藥品集中採購招標中，本集團共十二個產品十 四個品規分別擬中標：二羥丙茶鹼注射液(2ml:0.3g)、富馬酸福莫特羅吸入溶液(2ml:20µg)、 馬來酸氟伏沙明片(100mg 及50mg)、注射用氯諾昔康(8mg)、鹽酸腎上腺素注射液(1ml:1mg)、 鹽酸溴己新注射液(2ml:4mg)、複方電解質注射液(500ml)、複方電解質注射液(II)(500ml 及 1000ml)、尼可地爾片(5mg)、硫酸沙丁胺醇注射液(1ml:0.5mg)、鹽酸貝尼地平片(8mg)及碳酸 氫鈉注射液 (50ml:4.2g)。 承董事局命 執行董事兼公司秘書 周興揚 香港， ...

Core Viewpoint - Recently, Shijiazhuang Four Drug Group announced the approval of its generic version of Benidipine Hydrochloride Tablets, which is considered equivalent to the original product. According to MoSheng Pharmaceutical data, over 20 pharmaceutical companies have received approval for this product so far [1][10]. Group 1: Product Overview - Benidipine Hydrochloride Tablets are calcium channel blockers that selectively inhibit calcium ion influx across vascular smooth muscle cell membranes, thereby reducing peripheral vascular resistance, which helps in lowering blood pressure and alleviating angina [4]. - The total sales of Benidipine Hydrochloride Tablets in the full terminal hospital market are expected to exceed 2 billion yuan in 2024, making it one of the top 10 cardiovascular system drugs in terms of sales [4][5]. Group 2: Market Competition - In the 2024 full terminal hospital market, Benidipine Hydrochloride Tablets exhibit a three-way competitive landscape. Yangtze River Pharmaceutical holds the leading market share at 27.61%, followed by North China Pharmaceutical with 25.24%, and Nanchang Hongyi Pharmaceutical at 16.31% [6]. Group 3: Industry Participation - Currently, 22 companies, including Shijiazhuang Four Drug, North China Pharmaceutical, and Yangtze River Pharmaceutical Group, have received approval for Benidipine Hydrochloride Tablets, with 4 companies participating in the eighth batch of centralized procurement [10]. - In terms of generic drug development, over 30 companies, including Jiangsu Wango Pharmaceutical and Hunan Jiudian Pharmaceutical, are in the process of applying for the generic version under category 4 [10][13].

Summary of Key Points Core Viewpoint - On October 21, 32 Hong Kong-listed companies conducted share buybacks, totaling 14.32 million shares and an aggregate amount of HKD 58.19 million [1]. Group 1: Buyback Details - The company YunGongChang repurchased 2.10 million shares for HKD 8.22 million, with a highest price of HKD 3.980 and a lowest price of HKD 3.880, bringing its total buyback amount for the year to HKD 119 million [1][2]. - LianYiRong Technology-W repurchased 2.38 million shares for HKD 7.45 million, with a highest price of HKD 3.180 and a lowest price of HKD 3.100, totaling HKD 218 million in buybacks for the year [1][2]. - Mengniu Dairy repurchased 0.50 million shares for HKD 7.26 million, with a highest price of HKD 14.550 and a lowest price of HKD 14.460, accumulating HKD 451 million in buybacks for the year [1][2]. Group 2: Buyback Rankings - The highest buyback amount on October 21 was from YunGongChang at HKD 8.22 million, followed by LianYiRong Technology-W at HKD 7.45 million, and Mengniu Dairy also featured prominently [1][2]. - In terms of share quantity, LianYiRong Technology-W led with 2.38 million shares repurchased, followed by ShiSiYao Group and YunGongChang, each with 2.10 million shares [1][2]. Group 3: Additional Insights - KJ Pharma-B conducted its first buyback of the year, while Mengniu Dairy has made multiple buybacks totaling HKD 451 million [2]. - A detailed table of buybacks on October 21 includes various companies, their respective share counts, amounts, and price ranges, highlighting the active buyback environment in the Hong Kong market [2][3].

Group 1 - Multiple companies conducted share buybacks on October 21, 2025, with a total of 30 companies listed [1] - The largest buyback was by Cloud Factory (N23027), repurchasing 2.1 million shares for a total of 8.22 million yuan [1][2] - Other notable buybacks include Linklogis Technology (W09959) with 2.38 million shares for 7.45 million yuan and Mengniu Dairy (02319) with 500,000 shares for 7.26 million yuan [2] Group 2 - Cumulative buyback amounts for the year show Cloud Factory (N23027) has repurchased a total of 26.62 million shares, representing 5.786% of its total share capital [2] - Linklogis Technology (W09959) has repurchased 67.82 million shares, accounting for 3.174% of its total share capital [2] - Other companies with significant cumulative buybacks include Stone Four Pharmaceutical (02005) with 39.20 million shares (1.328%) and Kangchen Pharmaceutical (01681) with 6.50 million shares (7.637%) [2][3]

备注：持股数变动有可能因供股、合股、拆股等情况引起，请注意对照实际情况进行辨别。 股票名称 机构名称 性质 变动前持股 变动后持股 持股比 石四药集团(02005) 曲继广 好仓 12.15 亿股 12.17 亿股 41.22%(最新) 41.15%(前次) () 黄晓凌 好仓 11.00 万股 0股 0%(最新) 0.07%(前次) 智通财经APP获悉，石四药集团(02005)、()于2025年10月22日进行了最新股东权益披露。 ...